23/12/2020 - 16:35

PharmAust to test anti-cancer tablet in human trials

23/12/2020 - 16:35

Bookmark

Save articles for future reference.

ASX-listed pharmaceutical innovator, PharmAust, will begin manufacturing Monepantel tablets for two important Phase 1 and Phase 2 human trials to study the drug’s impact on Motor Neuron Disease and certain cancers. It will be the first time PharmAust has used its Monepantel drug in tablet form to investigate its anti-cancer activity in humans.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options